VRDN Q3 2020 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-1.48

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$615,000

Balance Sheet

Total Assets

$33M

Total Liabilities

$12M

Stockholders' Equity

$21M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$695,000	-100.0%
Gross Profit	$0	-$8M	+100.0%
Operating Income	-$5M	-$11M	+51.8%
Net Income	-$5M	-$11M	+51.1%